Old Mission Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Old Mission Capital’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,797	Closed	-$670K	–	1474
2022 Q1	$670K	Sell	10,797 -29,838	-73%	-$1.83M	0.02%	619
2021 Q4	$3.3M	Buy	40,635 +15,152	+59%	+$1.3M	0.14%	147
2021 Q3	$2.42M	Buy	25,483 +21,629	+561%	+$2.19M	0.1%	186
2021 Q2	$380K	Sell	3,854 -13,881	-78%	-$1.21M	0.01%	703
2021 Q1	$1.48M	Buy	+17,735	New	+$1.67M	0.08%	271

Other funds holding BIB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MCC

Money Concepts Capital Palm Beach Gardens, Florida $1.81B AUM 21.93% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Old Mission Capital's BIB Position: Q2 2022 in Review

Old Mission Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2022, closing a stake of 10,797 shares — an estimated $670K sold.

Old Mission Capital first reported a position in BIB in Q1 2021 and held it in 5 quarters. The position peaked at $3.3M in Q4 2021. 24 funds tracked by Wall St. Rank hold BIB as of Q2 2022.

Old Mission Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2022 after selling out during the quarter.
Old Mission Capital sold 10,797 ProShares Ultra NASDAQ Biotechnology shares in Q2 2022, an estimated $670K.
Old Mission Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2021 and held it in 5 quarters.
Old Mission Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $3.3M in Q4 2021.
24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2022.

Based on Old Mission Capital's 13F filing for Q2 2022, filed 5 Aug 2022.